POTENTIAL ASSOCIATION OF REMDESIVIR AND HYPERKALEMIA: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE

被引：0
|
作者：
Das, A. [1 ]
Vajapu, M. [1 ]
机构：
[1] Ramaiah Univ Appl Sci, Bangalore, KA, India
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH43
引用
收藏
页码：S172 / S172
页数：1
相关论文
共 50 条
  • [41] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System DatabaseA Disproportionality Analysis
    Behrooz K. Shamloo
    Pankdeep Chhabra
    Andrew N. Freedman
    Arnold Potosky
    Jennifer Malin
    Sheila Weiss Smith
    [J]. Drug Safety, 2012, 35 : 507 - 518
  • [42] Cardiovascular adverse events associated with parp inhibitors: A disproportionality analysis of FDA adverse event reporting system
    Viswam, Subeesh Kulangara
    Kheterpal, Aarushi
    Dhas, Ashwin
    Zeba, Zeba
    Shettigar, Amrutha
    Lukose, Lipin
    Kaur, Gursimran
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 452 - 452
  • [43] Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023
    Lin, Jinger
    Chen, Xiangqi
    Luo, Min
    Zhuo, Qianwei
    Zhang, Haosong
    Chen, Nuo
    Zhuo, Yunqian
    Han, Yue
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [44] Association of sacubitril/valsartan with hypoacusis unveiled through disproportionality analysis in US FDA adverse event reporting system (FAERS)
    Chiranjeevi, Pudi
    Saraswathy, G. R.
    Viswam, Subeesh Kulangara
    Swaroop, Ann Mary
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 131 - 131
  • [45] Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database
    Ke, Chengjie
    Chen, Maohua
    Huang, Yaping
    Chen, Yan
    Lin, Cuihong
    Huang, Pinfang
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (07) : 5253 - 5264
  • [46] Safety of fluoxetine use in children and adolescents: a disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database
    Iole N. Christodoulos
    Te-yuan Chyou
    Prasad S. Nishtala
    [J]. European Journal of Clinical Pharmacology, 2020, 76 : 1775 - 1776
  • [47] Safety of fluoxetine use in children and adolescents: a disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database
    Christodoulos, Iole N.
    Chyou, Te-yuan
    Nishtala, Prasad S.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (12) : 1775 - 1776
  • [48] Atypical antipsychotic drugs and diabetes mellitus in the USFDA adverse event reporting system (AERS) database in pediatric and adult patients
    Doraiswamy, P. Murali
    Arani, Ramin A.
    Gan, David
    Pikalov, Andrei
    Tran, Quynh-Van
    Mankoski, Raymond
    Baker, Ross A.
    [J]. BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 283S - 284S
  • [49] Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the US Food and Drug Administration Adverse Event Reporting System
    Li, Xiaotong
    Zhou, Liyuan
    Gaggl, Martina
    Kinlaw, Alan C.
    Gou, Zhuoyue
    Xu, Yang
    Wei, Jingkai
    Wang, Tiansheng
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (02) : 509 - 514
  • [50] Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system
    Jin, Yiyi
    Fan, Miao
    Zheng, Xiaomeng
    Zhu, Suyan
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
12345